CPT 93319, in plain terms, covers Add-on for 3D echo imaging with post-processing, billed with a transesophageal echo done for any reason or with a transthoracic echo done for a congenital heart defect. CPT 93319 is referenced in 2 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 93319 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 93319 on AAPC
Blue Cross Blue Shield Rhode Island is implementing major policy changes effective January 1, 2026, including new prior authorization requirements for physical therapy after 14 visits, removing prior authorization from numerous cardiology/radiology procedures, and updating coverage for various genetic testing and specialty procedures. Multiple CPT codes are changing authorization status and coverage requirements across Medicare Advantage and commercial plans.
Aetna considers FDA-approved leadless cardiac pacemakers, such as the Micra and Aveir systems, medically necessary when the member has symptomatic paroxysmal or permanent high-grade atrioventricular block, symptomatic bradycardia-tachycardia syndrome, or sinus node dysfunction (sinus bradycardia or sinus pauses), and also has a significant contraindication that precludes placement of conventional single chamber ventricular pacemaker leads. The listed contraindications are a history of an endovascular or cardiovascular implantable electronic device (CIED) infection or high risk for infection, limited access for trans-venous pacing, and the presence of a bio-prosthetic tricuspid valve. Aetna considers leadless pacemakers experimental, investigational, or unproven for all other indications, and considers a leadless pacemaker combined with cardiac resynchronization therapy, or with a subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death, experimental, investigational, or unproven.
Watch 93319
Get one email when a payer policy names 93319, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 93319
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 93319 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.